BioPharma Dive November 15, 2024
Companies need to reach the clinic quickly to prove they have a drug that can stand apart from competitors, according to executives and investors who spoke on a BioPharma Dive panel.
Failure is more common than success for young biotechnology companies attempting to get a new drug onto the market. Drug development is rife with pitfalls, from disappointing clinical trial results to funding woes that can end a program prematurely.
Companies should seek an edge by reducing risk, setting their would-be products apart and communicating clearly with investors on when their bet may pay off, three biotech veterans said during a panel hosted by BioPharma Dive on Nov. 13.
“We need to [have] an eye to a product or a...
Today's Sponsors
Today's Sponsor